188 related articles for article (PubMed ID: 14672734)
21. Development of potent non-estrogenic estrone sulfatase inhibitors.
Li PK; Chu GH; Guo JP; Peters A; Selcer KW
Steroids; 1998; 63(7-8):425-32. PubMed ID: 9654650
[TBL] [Abstract][Full Text] [Related]
22. A-ring-substituted estrogen-3-O-sulfamates: potent multitargeted anticancer agents.
Leese MP; Hejaz HA; Mahon MF; Newman SP; Purohit A; Reed MJ; Potter BV
J Med Chem; 2005 Aug; 48(16):5243-56. PubMed ID: 16078843
[TBL] [Abstract][Full Text] [Related]
23. Carbonic anhydrase inhibitors. Inhibition of cytosolic isozymes I and II and transmembrane, tumor-associated isozyme IX with sulfamates including EMATE also acting as steroid sulfatase inhibitors.
Winum JY; Vullo D; Casini A; Montero JL; Scozzafava A; Supuran CT
J Med Chem; 2003 May; 46(11):2197-204. PubMed ID: 12747791
[TBL] [Abstract][Full Text] [Related]
24. In vivo activity of 4-methylcoumarin-7-O-sulfamate, a nonsteroidal, nonestrogenic steroid sulfatase inhibitor.
Purohit A; Woo LW; Singh A; Winterborn CJ; Potter BV; Reed MJ
Cancer Res; 1996 Nov; 56(21):4950-5. PubMed ID: 8895749
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of steroid sulfatase with 4-substituted estrone and estradiol derivatives.
Phan CM; Liu Y; Kim BM; Mostafa Y; Taylor SD
Bioorg Med Chem; 2011 Oct; 19(20):5999-6005. PubMed ID: 21925885
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of estrone sulfate-induced uterine growth by potent nonestrogenic steroidal inhibitors of steroid sulfatase.
Ciobanu LC; Luu-The V; Martel C; Labrie F; Poirier D
Cancer Res; 2003 Oct; 63(19):6442-6. PubMed ID: 14559834
[TBL] [Abstract][Full Text] [Related]
27. 3Beta-sulfamate derivatives of C19 and C21 steroids bearing a t-butylbenzyl or a benzyl group: synthesis and evaluation as non-estrogenic and non-androgenic steroid sulfatase inhibitors.
Ciobanu LC; Boivin RP; Luu-The V; Poirier D
J Enzyme Inhib Med Chem; 2003 Feb; 18(1):15-26. PubMed ID: 12751816
[TBL] [Abstract][Full Text] [Related]
28. Steroid sulfatase: molecular biology, regulation, and inhibition.
Reed MJ; Purohit A; Woo LW; Newman SP; Potter BV
Endocr Rev; 2005 Apr; 26(2):171-202. PubMed ID: 15561802
[TBL] [Abstract][Full Text] [Related]
29. Solid-phase parallel synthesis of 17alpha-substituted estradiol sulfamate and phenol libraries using the multidetachable sulfamate linker.
Ciobanu LC; Poirier D
J Comb Chem; 2003; 5(4):429-40. PubMed ID: 12857111
[TBL] [Abstract][Full Text] [Related]
30. Synthesis and Biological Evaluation of Fluorinated 3-Phenylcoumarin-7-O-Sulfamate Derivatives as Steroid Sulfatase Inhibitors.
Demkowicz S; Daśko M; Kozak W; Krawczyk K; Witt D; Masłyk M; Kubiński K; Rachon J
Chem Biol Drug Des; 2016 Feb; 87(2):233-8. PubMed ID: 26280898
[TBL] [Abstract][Full Text] [Related]
31. The development of A-ring modified analogues of oestrone-3-O-sulphamate as potent steroid sulphatase inhibitors with reduced oestrogenicity.
Purohit A; Vernon KA; Hummelinck AE; Woo LW; Hejaz HA; Potter BV; Reed MJ
J Steroid Biochem Mol Biol; 1998 Mar; 64(5-6):269-75. PubMed ID: 9618028
[TBL] [Abstract][Full Text] [Related]
32. D-ring modified estrone derivatives as novel potent inhibitors of steroid sulfatase.
Fischer DS; Woo LW; Mahon MF; Purohit A; Reed MJ; Potter BV
Bioorg Med Chem; 2003 Apr; 11(8):1685-700. PubMed ID: 12659755
[TBL] [Abstract][Full Text] [Related]
33. Role of steroid sulfatase in local formation of estrogen in post-menopausal breast cancer patients.
Nakata T; Takashima S; Shiotsu Y; Murakata C; Ishida H; Akinaga S; Li PK; Sasano H; Suzuki T; Saeki T
J Steroid Biochem Mol Biol; 2003 Sep; 86(3-5):455-60. PubMed ID: 14623544
[TBL] [Abstract][Full Text] [Related]
34. Discovery of a sulfamate-based steroid sulfatase inhibitor with intrinsic selective estrogen receptor modulator properties.
Ouellet C; Maltais R; Ouellet É; Barbeau X; Lagüe P; Poirier D
Eur J Med Chem; 2016 Aug; 119():169-82. PubMed ID: 27155470
[TBL] [Abstract][Full Text] [Related]
35. Synthesis, in vitro and in vivo activity of benzophenone-based inhibitors of steroid sulfatase.
Hejaz HA; Woo LW; Purohit A; Reed MJ; Potter BV
Bioorg Med Chem; 2004 May; 12(10):2759-72. PubMed ID: 15110857
[TBL] [Abstract][Full Text] [Related]
36. Sulfamates and their therapeutic potential.
Winum JY; Scozzafava A; Montero JL; Supuran CT
Med Res Rev; 2005 Mar; 25(2):186-228. PubMed ID: 15478125
[TBL] [Abstract][Full Text] [Related]
37. Steroid sulfatase: a new target for the endocrine therapy of breast cancer.
Stanway SJ; Delavault P; Purohit A; Woo LW; Thurieau C; Potter BV; Reed MJ
Oncologist; 2007 Apr; 12(4):370-4. PubMed ID: 17470679
[TBL] [Abstract][Full Text] [Related]
38. Steroid sulfatase mediated growth Sof human MG-63 pre-osteoblastic cells.
Dias NJ; Selcer KW
Steroids; 2014 Oct; 88():77-82. PubMed ID: 25042472
[TBL] [Abstract][Full Text] [Related]
39. Bicyclic derivatives of the potent dual aromatase-steroid sulfatase inhibitor 2-bromo-4-{[(4-cyanophenyl)(4h-1,2,4-triazol-4-yl)amino]methyl}phenylsulfamate: synthesis, SAR, crystal structure, and in vitro and in vivo activities.
Wood PM; Woo LW; Labrosse JR; Thomas MP; Mahon MF; Chander SK; Purohit A; Reed MJ; Potter BV
ChemMedChem; 2010 Sep; 5(9):1577-93. PubMed ID: 20632362
[TBL] [Abstract][Full Text] [Related]
40. Sulfatase inhibitors for recidivist breast cancer treatment: A chemical review.
Shah R; Singh J; Singh D; Jaggi AS; Singh N
Eur J Med Chem; 2016 May; 114():170-90. PubMed ID: 26974384
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
